[go: up one dir, main page]

WO2006007400A9 - Methods of diagnosing and treating obesity, diabetes and insulin resistance - Google Patents

Methods of diagnosing and treating obesity, diabetes and insulin resistance Download PDF

Info

Publication number
WO2006007400A9
WO2006007400A9 PCT/US2005/021297 US2005021297W WO2006007400A9 WO 2006007400 A9 WO2006007400 A9 WO 2006007400A9 US 2005021297 W US2005021297 W US 2005021297W WO 2006007400 A9 WO2006007400 A9 WO 2006007400A9
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosing
diabetes
methods
insulin resistance
treating obesity
Prior art date
Application number
PCT/US2005/021297
Other languages
French (fr)
Other versions
WO2006007400A2 (en
Inventor
Shonna A Moodie
Fang Zhang
Paul G Rack
Jin Shang
Brian E Lavan
Bernard Allan
Chi-Wai Wong
Francine Gregoire
Grace Perez
Steve Waters
Original Assignee
Metabolex Inc
Shonna A Moodie
Fang Zhang
Paul G Rack
Jin Shang
Brian E Lavan
Bernard Allan
Chi-Wai Wong
Francine Gregoire
Grace Perez
Steve Waters
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolex Inc, Shonna A Moodie, Fang Zhang, Paul G Rack, Jin Shang, Brian E Lavan, Bernard Allan, Chi-Wai Wong, Francine Gregoire, Grace Perez, Steve Waters filed Critical Metabolex Inc
Priority to JP2007516737A priority Critical patent/JP2008503212A/en
Publication of WO2006007400A2 publication Critical patent/WO2006007400A2/en
Publication of WO2006007400A9 publication Critical patent/WO2006007400A9/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2005/021297 2004-06-16 2005-06-15 Methods of diagnosing and treating obesity, diabetes and insulin resistance WO2006007400A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007516737A JP2008503212A (en) 2004-06-16 2005-06-15 Methods for diagnosis and treatment of obesity, diabetes and insulin resistance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58044804P 2004-06-16 2004-06-16
US60/580,448 2004-06-16

Publications (2)

Publication Number Publication Date
WO2006007400A2 WO2006007400A2 (en) 2006-01-19
WO2006007400A9 true WO2006007400A9 (en) 2009-04-09

Family

ID=35784320

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/021297 WO2006007400A2 (en) 2004-06-16 2005-06-15 Methods of diagnosing and treating obesity, diabetes and insulin resistance

Country Status (2)

Country Link
JP (1) JP2008503212A (en)
WO (1) WO2006007400A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734795B2 (en) 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2533667A1 (en) * 2003-07-29 2005-02-10 Universite Laval Obesity markers and uses thereof
GB0520568D0 (en) * 2005-10-10 2005-11-16 Paradigm Therapeutics Ltd Receptor
US20100298217A1 (en) * 2007-05-30 2010-11-25 Evan Richard Stanley Csf-1r mutants
KR101572162B1 (en) * 2013-04-10 2015-11-26 한국생명공학연구원 Regulation of brown adipocyte differentiation using PTP-RE
WO2015200901A1 (en) 2014-06-26 2015-12-30 The Trustees Of Columbia University In The City Of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
US11291706B2 (en) 2015-07-16 2022-04-05 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using Slit2
WO2017049010A1 (en) * 2015-09-15 2017-03-23 The Trustees Of Columbia University In The City Of New York Use of aldehyde dehydrogenase as biomarker for beta-cell dysfunction and loss
CA3071611A1 (en) 2017-07-31 2019-02-07 The Trustees Of Indiana University Modified ddah polypeptides comprising a pharmacokinetic enhancing moiety, improved pharmacology and their uses
US20230287432A1 (en) * 2020-02-27 2023-09-14 Alnylam Pharmaceuticals, Inc. G protein-coupled receptor 146 (gpr146) irna compositions and methods of use thereof
CN112472790B (en) * 2020-12-25 2022-12-20 同济大学 Application of small albumin inhibitor in preparing products for preventing and treating obesity and diseases caused by obesity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734795B2 (en) 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof

Also Published As

Publication number Publication date
WO2006007400A2 (en) 2006-01-19
JP2008503212A (en) 2008-02-07

Similar Documents

Publication Publication Date Title
IL246402A (en) Therapeutic agent for treating obesity, diabetes and diseases associated with impaired glucose tolerance
HK1098700A1 (en) Use of drug combinations for treating insulin resistance
EP2120959A4 (en) Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia
EG25277A (en) Subterranean treatment fluids, friction reducing copolymers, and associated methods.
WO2007100535A3 (en) Oxyntomodulin derivatives
IL187859A0 (en) Diagnosis and prognosis of diabetes
IL176648A0 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
PL1841363T3 (en) Catheter-free implantable needle biosensor
GB0619860D0 (en) Treatment of insulin resistance and disorders associated therewith
IL174033A0 (en) Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent
EP1890708A4 (en) Glucose inducible insulin expression and methods of treating diabetes
IL198112A0 (en) 3-aminoimidazo [1,2-a]pyridine derivatives having an sglt1-and sglt2-inhibiting action for the treatment of type 1 and type 2 diabetes
EP1799217A4 (en) Compounds and methods of treating insulin resistance and cardiomyopathy
GB2439838B (en) Inter-system binding method and application based on hardware security unit
EP1794235A4 (en) Electroconductive resin composition, production method and use thereof
WO2006007400A9 (en) Methods of diagnosing and treating obesity, diabetes and insulin resistance
EP1733749A4 (en) Syringe with connector, connector for syringe, and syringe
EP1825002A4 (en) Markers for metabolic syndrome obesity and insulin resistance
WO2003102163A8 (en) Methods of diagnosing and treating diabetes and insulin resistance
EP1774029A4 (en) Method for detecting the risk of and for treatment of type 2 diabetes
AU2003243427A1 (en) Methods of diagnosing and treating diabetes and insulin resistance
AU2001292658A1 (en) Method for treatment of insulin resistance in obesity and diabetes
ATE504595T1 (en) IL-22 FOR THE TREATMENT OF OBESITY, DIABETES, HYPERLIPIDEMIA, HYPERGLYCEMIA AND INSULIN RESISTANCE
HK1076721A1 (en) A chinese traditional medical composition for treating diabetes and method for preparing the same
EP1984734B8 (en) Sigma-2 receptor, method of screening of specific ligands and use of the same in diagnostic or therapeutic methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007516737

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase